CUSTOMIZED SUPPORT FOR SUSTAINED RELEASE DRUG DELIVERY THERAPIES
From FEASIBILITY to DEVELOPMENT to COMMERCIALIZATION
Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics and small molecules to meet the goals of patient-centric therapies, improved medicine and better healthcare economics.
Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support through our state-of-the art development and feasibility lab. Our objective is to help our customers reduce R&D time and improve the likelihood of successful drug commercialization.
INTRODUCING THE VITALDOSE® PLATFORM
Our VitalDose® Ethylene-Vinyl Acetate (EVA) copolymer drug-delivery platform is an enabling technology for drug-eluting implants, inserts and transdermal films. The platform is flexible and customizable to address a variety of formulation challenges when it comes to tailoring the release rate of your drug.
Watch the on-demand webinar, ENGINEERING DRUG DELIVERY TO IMPROVE THERAPEUTIC OUTCOMES: THE WHY AND HOW OF DRUG ELUTING IMPLANTS.
VitalDose® EVA has been approved for use in numerous pharmaceutical and medical device applications. We are actively supporting marketed products and development programs in:
Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. We partner with our customers to solve their most critical business needs and strive to make a positive impact on our communities and the world through our commitment to sustainability and The Celanese Foundation. Based in Dallas, Celanese employs approximately 7,700 employees worldwide and had 2019 net sales of $6.3 billion.
Celanese has supported key applications and the demanding requirements of the medical market for over 40 years, expanding design possibilities with our customers. We’re focused on developing new cutting-edge, chemistry-driven approaches to improve patient care. Our continuously expanding portfolio includes solutions and technologies across applications including drug delivery, medical devices, implantable devices, advanced surgical instruments and connected devices.
Posted Date: 12/1/2021
This record has been viewed 621 times.